Table 1.
Demographical Information for the Eight Study Patients
| Patient Number | P1 | P2 | P3 | P4 | P5 | P6 | P7 | P8 |
|---|---|---|---|---|---|---|---|---|
| Age, y | 59 | 55 | 47 | 54 | 62 | 60 | 51 | 68 |
| Sex | M | M | F | F | F | M | F | F |
| Smoking status | Current | Current | NS | NS | Current | Current | NS | NS |
| PMH | Splenectomy due to trauma, hemochromatosis | HTN, hyperlipidemia | NIDDM | HTN | HTN | HTN | ITP, sleep apnea, migraine | CA breast, DM, HTN, RA, Sjogren |
| Endocrinological treatment of GD | ATD | ATD | RAI | ATD | RAI | ATD | None | T4 |
| Chronology of TAO in relation to thyroid disease | Before GD | After GD | After GD | After GD | After GD | After GD | With GD | After GD |
| Duration of TAO prior to corticosteroids | 3 | N/A | N/A | 4 | 2 | N/A | 2 | 5 |
| Duration of corticosteroids prior to RTX | 13 | 0 | 0 | 1 | 2 | 0 | 1 | 10 |
| Duration of TAO prior to RTX | 16 | 4 | 6 | 5 | 4 | 5 | 7 | 15 |
| Clinical response to CS | Progression; CON during CS taper | Progression | Progression | Progression | Progression | Progression | Progression | Progression; CON |
| Additional immunosuppressant before RTX | Cellcept | None | None | None | None | None | None | PMP |
| Episode of CON (side) | Right | Bilateral | Left | Left | Right | Bilateral | None | Right |
| Orbital decompression (number eyes) | 1 (9 mo prior to RTX) | None | None | 1 (9 mo after RTX) | None | None | 2 (2 mo after RTX) | 1 (after first RTX infusion) |
Abbreviations: ATD, antithyroid drugs; CA, cancer; CS for corticosteroids; DM, diabetes mellitus; HTN, hypertension; PMP for pulsed methylprednisolone; CS, current smoker; F, female; M, male; N/A, not available; NIDDM, non-insulin-dependent diabetes mellitus; NS, nonsmoker; RAI, radioactive iodine; RA, rheumatoid arthritis; ITP, idiopathic thrombocytopenic purpurea; RTX, rituximab; CON, compressive optic neuropathy; GO, Graves' ophthalmopathy. The table includes patient age, gender, smoking status, medical history, treatment of hyperthyroidism, chronology of GD, duration of GO prior to corticosteroids, duration of corticosteroids prior to rituximab treatment, duration of GO prior to rituximab treatment, additional immunosuppressant before rituximab (if applicable), whether compressive optic neuropathy was present, and whether orbital decompression surgery had been done.